top of page

Dana-Farber Cancer Institute investigators describe a personalized cancer vaccine trial in kidney cancer that was published in Nature. All nine patients did not see their cancer recur.

  • blonca9
  • Feb 6
  • 1 min read

Toni Choueiri and Patrick Ott describe how this peptide-based vaccine was personalized to numerous neoantigens for the patients in this adjuvant setting trial. Plus, next steps in various cancers.




Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

evaluate-logo-png_seeklogo-457165-2_edited.png

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

bottom of page